Peer-reviewed journals

• Personal risk or societal benefit? Investigating adults’ support for COVID-19 childhood vaccination.
  C. Chiavenna, L.P. Leone, A. Melegaro, T. Rotesi, S.E. Bokemper, E.E. Paintsil, A.A. Malik, G.A. Huber, S.B. Omer, M. Cucciniello, P. Pin (2023).
  Vaccine 41(25), 3683-3687. [link]

• HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
  A.K. Sullivan, J. Saunders, M. Desai, A. Cartier, HD. Mitchell, S. Jaffer, D. Ogaz, C. Chiavenna, A. Charlett, V. Diamente, R. Golombek, K. Manavi, C. Priestley, L.J. Waters, A. Milinkovic, A. McOwan, C. Estcourt, C.A. Sabin, A. Rodger, D. Gold, B.G. Gazzard, S. McCormack, N. Gill (2023).
  The Lancet HIV 10(12): e790-e806. [link]

• Methods for modelling excess mortality across England during the COVID-19 pandemic.
  S. Barnard, C. Chiavenna, S. Fox, A. Charlett, Z. Waller, N. Andrews, P. Goldblatt, P. Burton, D. De Angelis (2022).
  Statistical Methods in Medical Research 31(9), 1790-1802. [link]

• Estimating age-stratified influenza-associated invasive pneumococcal disease in England: A time-series model based on population surveillance data.
  C. Chiavenna, A.M. Presanis, A. Charlett, S. de Lusignan, S. Ladhani, R.G. Pebody, D. De Angelis (2019).
  PLoS Medicine 16(6): e1002829. [link]

• Predictors of first ischemic lower limb ulcer in dialysis patients: an observational cohort study.
  S. Andrulli, C. Chiavenna, M.C. Bigi, M. Crepaldi, C. Dell’Oro, F. Tentori, C. Manzoni, G. Bacchini, M.M. Corti, G. Pontoriero (2018).
  Journal of Nephrology 31, 435-443. [link]

• Postmenopausal hormone therapy and risk of stroke: A pooled analysis of data from population-based cohort studies
  G.D. Carrasquilla, P. Frumento, A. Berglund, C. Borgfeldt, M. Bottai, C. Chiavenna, M. Eliasson, G. Engström, G. Hallmans, J. Jansson, P.K. Magnusson, P.M. Nilsson, N.L. Pedersen, A. Wolk, K. Leander (2017).
  PLoS Medicine 14(11): e1002445. [link]

Conference proceedings

• Sequence Analysis for Vaccination Data.
  C. Chiavenna, D. Bolano, A. Melegaro (2024).
  Società Italiana di Statistica

• PrEP Impact trial participation among trans and non-binary sexual health attendees in England.
  M. Hibbert, R. Osman, T. Suchak, M. Ross, E. Mason, Q. Enayat, H. Mitchell, C. Chiavenna, K. Nambiar, A. Cartier, S. Jaffer, V. Diamente, J. Saunders, A. Sullivan, The PrEP Impact Research Group (2021).
  HIV Medicine 22(S3), BPD2/4 (moderated poster abstract).

• HIV and STI incidence among MSM users and non-users of HIV PrEP in England: results from the Impact trial.
  A. Sullivan, C. Chiavenna, A. Cartier, S. Jaffer, H. Mitchell, D. Ogaz, E. Mason, R. Osman, F. Coukan, V. Diamente, R. Golombek, D. Richardson, S. Strachan, K. Manavi7, McCormack, C. Priestley, L. Waters, C. Estcourt, D. Gold, D. Goldberg, T. Peto, A. Rodger, C. Sabin, A. Charlett, M. Desai, J. Saunders, N. Gill, on behalf of the Impact Study Group (2021).
  HIV Medicine 22 (S3), BPD2/7 (moderated poster abstract).

• Distance travelled to access pre-exposure prophylaxis (PrEP) for HIV prevention on the PrEP Impact trial in England during 2017-2020.
  E. Mason, R. Osman, M. Hibbert, Q. Enayat, H. Mitchell, C. Chiavenna, J. Saunders, A. Sullivan, P. Chhibbar, R. Golombek, S. McCormack, M. Desai, K. Manavi (2021).
  HIV Medicine 22(S2), P079 (poster abstract).

• The HIV pre-exposure prophylaxis (PrEP) Impact trial: baseline demographics, coverage and first regimen choice.
  A. Sullivan, M. Desai, J. Saunders, A. Cartier, S. Jaffer, A. Milinkovic, V. Diamente, M. Hibbert, E. Mason, H.D. Mitchell, R. Osman, C. Chiavenna, A. Charlett, D. Gold, R. Gilson, N. Gill (2021).
  HIV Medicine 22(S2), O013 (talk abstract).

• STI incidence among participants in the HIV Pre-Exposure Prophylaxis (PrEP) impact trial in England.
  C. Chiavenna, H.D. Mitchell, R. Osman, E. Mason, M.P. Hibbert, Q. Enayat, A. Cartier, S. Jaffer, V. Diamente, R. Golombek, C. Estcourt, C. Sabin, J. Saunders, A. Charlett, A. Sullivan (2021).
  Journal of the International AIDS Society 24(S4), OAC04 (talk abstract).

• Baseline demographics, coverage and first regimen choice of participants in the HIV Pre-Exposure Prophylaxis (PrEP) Impact trial.
  A. Sullivan, J. Saunders, A. Cartier, S. Jaffer, A. Milinkovic, C. Priestley, K. Manavi, L. Waters, E. Mason, M. Hibbert, C. Chiavenna, A. Charlett, C. Estcourt, C. Sabin, A. Rodger, D. Gold, A. McOwan, N. Gill, M. Desai (2021).
  Journal of the International AIDS Society 24(S4), PE16.35LB (poster abstract).

• Pneumococcal vaccine and serotype replacement in England: the bias of increased reporting.
  C. Chiavenna, A. Presanis, A. Charlett, S. Ladhani, D. De Angelis (2020).
  European Journal of Public Health 30 (S5), 165.1257 (poster abstract).

• The association between menopausal hormone therapy and coronary heart disease depends on timing of initiation in relation to menopause onset. Results based on pooled individual participant data from The Combined Cohorts of Menopausal Women - Studies of Register Based Health Outcomes in Relation to Hormonal Drugs (COMPREHEND) study
  G.D. Carrasquilla, C. Chiavenna, M. Bottai, P.K. Magnusson, M. Santacatterina, A. Wolk, G. Hallmans, J. Jansson, G. Engstrom, C. Borgfeldt, N.L. Pedersen, M. Eliasson, A. Berglund, K. Leander (2015).
  Menopause: The Journal of the North American Menopause 22 (12), 1373-1373.